



## **Scandinavian ChemoTech's Animal Care Surpasses 2,500 Treatment-kits sold Worldwide**

*Scandinavian ChemoTech's Animal Care, a pioneer in veterinary oncology innovation, is proud to announce a significant milestone: more than 2,500 kits for TSE treatments have been sold to improve the health of animals worldwide using its advanced vetIQure TSE (Tumour Specific Electroporation) technology. Beyond the number, this achievement represents thousands of families who have gained more time, comfort, and hope with their beloved companions.*

Since launch, vetIQure TSE technology has been embraced by veterinarians across the globe, with 70% of the treatments performed in the United States and 30% in international markets. Its rapid adoption reflects not only the technology's clinical value, but also the growing commitment among veterinarians to offer advanced cancer care to pet owners everywhere.

Importantly, over half of these treatments have been carried out in clinics belonging to leading global veterinary groups, underscoring the trust placed in Scandinavian ChemoTech Animal Care's solutions by large-scale providers. The remaining treatments took place in institutional settings and privately owned practices, highlighting the technology's adaptability to serve patients across diverse care environments.

*"Every treatment represents a pet whose quality of life has been improved, and a family who has been given more moments of love and connection,"* said Mohan Frick, CEO at Scandinavian ChemoTech. *"We are humbled by the impact vetIQure TSE technology is making and remain committed to helping veterinarians fight cancer with innovative tools."*

Scandinavian ChemoTech's subsidiary VQ Animal Care Inc. is committed to expanding access to its life-changing oncology technology. From 38 successful installations to date, the company is now focused on ambitious upcoming milestones:

- 100 devices deployed globally – broadening the reach of advanced oncology treatment.
- More than 5,000 animal treatments completed – ensuring that pets worldwide benefit from cutting-edge cancer care.

These milestones will help veterinarians across the globe bring new hope to patients and families, advancing standards in veterinary oncology and making world-class treatment more accessible than ever before.

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 20-08-2025 11:50 CET.

*For further information please contact:*

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: [ir@chemotech.se](mailto:ir@chemotech.se)

***Certified Adviser: Redeye AB***

**Scandinavian ChemoTech AB (publ)**

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: [www.chemotech.se](http://www.chemotech.se).